/INIT.ST
INIT.ST Stock - Initiator Pharma A/S
Healthcare|BiotechnologySTO
$2.93+2.81%
+$0.08 (+2.81%) • Dec 23
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.18
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $3.22
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for INIT.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.90 – $2.96
TARGET (TP)$3.37
STOP LOSS$2.70
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.14
52W High$8.25
52W Low$2.56
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-11,073 | $-23,412 | $-38,425 | $-21,626 | $-9,299 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-14,502 | $-27,029 | $-41,740 | $-23,072 | $-10,531 |
| Net Income | $-12,932 | $-22,873 | $-38,455,000 | $-21,064,000 | $-8,697,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.23 | $-0.00 | $-0.80 | $-0.60 | $-0.32 |
Company Overview
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021 for targeting an orphan drug indication in severe neuropathic pain. The company's pre-clinical stage candidates include IPNP2015 for the treatment of chronic pain; and IPDP2015 for depression. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
INIT.STBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.09
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q1 2026 | Feb 20, 2026 | — | — | — | — |
Q4 2025 | Nov 21, 2025 | — | $-0.09 | — | — |
Q3 2025 | Aug 22, 2025 | — | $-0.10 | — | — |
Q2 2025 | May 9, 2025 | — | $-0.07 | — | — |
Q1 2025 | Feb 28, 2025 | — | $-0.02 | — | — |
Q4 2024 | Nov 29, 2024 | — | $-0.09 | — | — |
Q3 2024 | Aug 23, 2024 | — | $-0.13 | — | — |
Q2 2024 | May 10, 2024 | — | $-0.12 | — | — |
Q1 2024 | Feb 23, 2024 | — | $0.04 | — | — |
Q4 2023 | Nov 10, 2023 | — | $-0.13 | — | — |
Q3 2023 | Aug 25, 2023 | — | $-0.29 | — | — |
Q2 2023 | May 5, 2023 | — | $-0.25 | — | — |
Q1 2023 | Feb 17, 2023 | — | $-0.10 | — | — |
Q4 2022 | Nov 4, 2022 | — | $-0.19 | — | — |
Q3 2022 | Aug 26, 2022 | — | $-0.42 | — | — |
Q2 2022 | May 6, 2022 | — | $-0.44 | — | — |
Q1 2022 | Feb 18, 2022 | — | $-0.15 | — | — |
Q4 2021 | Nov 19, 2021 | — | $-0.33 | — | — |
Q3 2021 | Aug 20, 2021 | — | $-0.25 | — | — |
Latest News
Loading news...
Frequently Asked Questions about INIT.ST
What is INIT.ST's current stock price?
Initiator Pharma A/S (INIT.ST) is currently trading at $2.93 per share. The stock has moved +2.81% today.
What is the analyst price target for INIT.ST?
No analyst price targets are currently available for this stock.
What sector is Initiator Pharma A/S in?
Initiator Pharma A/S operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is INIT.ST's market cap?
Initiator Pharma A/S has a market capitalization of $0.20 billion, making it a small-cap company.
Does INIT.ST pay dividends?
No, Initiator Pharma A/S does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALZ.ST
Alzinova AB (publ)
$0.82
Mkt Cap: $0.1B
ANNX.ST
Annexin Pharmaceuticals AB (publ)
$19.00
Mkt Cap: $0.1B
BIOWKS.ST
Bio-Works Technologies AB (publ)
$2.25
Mkt Cap: $0.2B
CLS-B.ST
Clinical Laserthermia Systems AB (publ)
$7.00
Mkt Cap: $0.2B
IRLAB-A.ST
IRLAB Therapeutics AB (publ)
$1.97
Mkt Cap: $0.2B
ISOFOL.ST
Isofol Medical AB (publ)
$0.72
Mkt Cap: $0.2B
IZAFE-B.ST
iZafe Group AB (publ)
$0.47
Mkt Cap: $0.1B
KDEV.ST
Karolinska Development AB (publ)
$0.43
Mkt Cap: $0.1B
LIPUM.ST
Lipum AB (publ)
$14.55
Mkt Cap: $0.3B
SENZA.ST
SenzaGen AB
$5.98
Mkt Cap: $0.2B
Explore stocks similar to INIT.ST for comparison